GSK
ZEJULA (niraparib)
GSK presented the data of Zejula, a PARP inhibitor, which improves PFS in women with first-line platinum responsive advanced ovarian cancer.
About PRIMA trial
PRIMA trial is Phase 3, double-blind, placebo-controlled study. The drug is indicated in patients with first-line ovarian cancer following platinum-based chemotherapy. The trial was conducted in BRCA mutation tumors, HR-deficient BRCA wild type tumors, HR-proficient tumors.
Results presented were:
· Reduction in risk of disease progression by 38%
· In HR-deficient subgroup, after 24 months, 91% of women were alive compared to 85% of women administered with placebo
· Anaemia, thrombocytopenia, and neutropenia were the frequent adverse events reported
GSK3359609
GSK presented the data of GSK3359609 in combination with pembrolizumab in patients suffering from head and neck squamous cell carcinoma. GSK3359609 is an ICOS receptor agonist.
INDUCE-1
Patients on monotherapy were indicated with 1 mg/kg GSK3359609. Patients in combination were administered with 0.3mg/kg GSK3359609 and 200 mg pembrolizumab.
Results:
In the patients administered with combination therapy: the overall response rate was 24%. Median progression-free survival was 5.6 months. 6% response rate was observed in patients who were on monotherapy.
PFIZER
Bavencio (avelumab)
Pfizer presented the data of Bavencio plus axitinib in patients with advanced renal cell carcinoma (RCC). The abstract also showed the data of Bavencio as monotherapy and in combinations against different cancers.
About JAVELIN trial
The trial demonstrated efficacy in renal cell carcinoma (RCC), metastatic Merkel cell carcinoma (mMCC) and some other solid tumors. The trial is a randomized, multicenter, open-label study.
Results of the study were:
Patients with Advanced RCC who did not undergo Upfront Cytoreductive Nephrectomy: Bavencio + axitinib showed shrinkage in 34.5% of patients versus 9.7%, in patients who were administered with sunitinib.
Patients with Advanced RCC with Sarcomatoid Histology: Bavencio + axitinib showed PFS of 7.0 months vs. 4.0 months in patients who were administered with sunitinib.
JANSSEN
ERLEADA (apalutamide)
Janssen presented the data of Erleada in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The drug is indicated in combination with androgen deprivation therapy.
About SPARTAN study:
SPARTaN is a Phase 3 study following a second interim analysis. The results show 25% reduction in death in patients treated with Erleada + androgen deprivation therapy compared to placebo + ADT.